Importantly, combination treatments targeting EGFR and YAP/TAZ‐TEAD were effective in restraining lung tumorigenesis by blocking agrin as a central player in this oncogenic module, thereby revealing new vistas to combat EGFR‐driven lung malignancies. This evidence concerns the gene EGFR and medical procedure.